Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MOLECULE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET TYPE OF END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 CONTACT LIST OF MARKETING PERSONS INVOLVE IN PURCHASE OF ACTIVE PHARMACEUTICAL INGREDIENTS
4.4 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET
5 REGULATORY FRAMEWORK
5.1 OVERVIEW
5.2 CURRENT GOODS MANUFACTURING PRACTICES
5.3 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN VIETNAM
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISEASE
6.1.2 INCREASE IN THE AGING POPULATION
6.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING
6.1.4 INCREASING DISEASE AWARENESS AND EDUCATION
6.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API)
6.2 RESTRAINTS
6.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS
6.2.2 HIGH MANUFACTURING COST
6.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API)
6.3 OPPORTUNITIES
6.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS
6.3.2 INCREASING HEALTHCARE EXPENDITURE
6.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)
6.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS
6.4 CHALLENGES
6.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19
6.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
7 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC CLASS
7.1 OVERVIEW
7.2 ANTIBIOTIC
7.3 CARDIOVASCULAR
7.4 LIPID LOWERING DRUGS
7.5 INFECTIOUS DISEASE
7.6 ANESTHETIC
7.7 NSAIDS
7.8 ANALGESIC
7.9 ANTIVIRAL
7.1 DERMATOLOGY
7.11 ONCOLOGY
7.12 ENDOCRINOLOGY
7.13 UROLOGY
7.14 GASTROENTEROLOGY
7.15 OPHTHALMOLOGY
7.16 HORMONAL AGENTS
7.17 MUSCLE RELAXANT
7.18 PARKINSON
7.19 PSORIASIS
7.2 EPILEPTIC
7.21 IMMUNOLOGY
7.22 HEMATOLOGY
7.23 ANTINEOPLASTIC
7.24 IMMUNOSUPPRESSIVE AGENTS
7.25 OTHERS
8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE
8.1 OVERVIEW
8.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
8.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
9 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER
9.1 OVERVIEW
9.2 CAPTIVE MANUFACTURERS
9.2.1 CAPTIVE INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
9.2.2 CAPTIVE GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
9.3 MERCHANT MANUFACTURERS
9.3.1 MERCHANT INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
9.3.2 MERCHANT GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
10 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS
10.1 OVERVIEW
10.2 CHEMICAL SYNTHETIC
10.2.1 SAXAGLIPTIN
10.2.2 ENOXAPARIN SODIUM
10.2.3 RUFINAMIDE
10.2.4 TAMOXIFEN
10.2.5 ARTEMISININ
10.2.6 LOSARTAN POTASSIUM
10.2.7 NAPROXEN
10.2.8 IBUPROFEN
10.2.9 ACETAMINOPHEN
10.2.10 SODIUM CHLORIDE
10.2.11 OTHERS
10.3 BIOTECH
10.3.1 MONOCLONAL ANTIBODIES
10.3.2 CYTOKINES
10.3.3 HORMONES & GROWTH FACTORS
10.3.4 BLOOD FACTORS
10.3.5 RECOMBINANT VACCINES
10.3.6 THERAPEUTIC ENZYMES BIOTECH
11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY
11.1 OVERVIEW
11.2 TRADITIONAL POTENCY ACTIVE PHARMACEUTICAL INGREDIENT
11.3 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENT
12 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, TYPE OF DRUG
12.1 OVERVIEW
12.2 PRESCRIPTION DRUGS
12.3 OVER-THE-COUNTER DRUGS
13 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, MOLECULE
13.1 OVERVIEW
13.2 SMALL MOLECULE
13.3 LARGE MOLECULE
14 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, APPLICATION
14.1 OVERVIEW
14.2 CLINICAL
14.3 RESEARCH
15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY END USER
15.1 OVERVIEW
15.2 PHARMACEUTICAL INDUSTRIES
15.2.1 LARGE
15.2.2 MEDIUM
15.2.3 SMALL
15.3 BIOTECHNOLOGY INDUSTRIES
15.3.1 LARGE
15.3.2 MEDIUM
15.3.3 SMALL
15.4 RESEARCH AND ACADEMIC INSTITUTES
15.5 OTHERS
16 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDERS
16.3 RETAIL SALES
16.4 OTHERS
17 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: VIETNAM
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 PFIZER, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 MEKOPHAR
19.2.1 COMPANY SNAPSHOT
19.2.2 RECENT FINANCIALS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 ASTRAZENECA
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 DIVI’S LABORATORIES LIMITED
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 SANOFI
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 DR. REDDY’S LABORATORY LTD.
19.6.1 COMPANY SNAPSHOT
19.6.2 RECENT FINANCIALS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 AUROBINDO PHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 BASF SE
19.8.1 COMPANY SNAPSHOT
19.8.2 RECENT FINANCIALS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 GSK PLC
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE FINANCIALS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 JUBILANT PHARMOVA LIMITED
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 LUPIN
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 NOVO NORDISK A/S
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENT
19.15 UNICHEM LABORATORIES
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 BELOW PROVIDED TABLE IS PROVIDING DATA OF DIFFERENT APIS WITH THEIR THERAPEUTIC APPLICATIONS UNDER THE CLINICAL TRIAL:
TABLE 2 BELOW ARE SOME MANUFACTURERS WHO ARE INVOLVED IN THE PRODUCTION OF ACTIVE PHARMACEUTICAL INGREDIENTS (API):
TABLE 3 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 4 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2021-2030 (USD MILLION)
TABLE 6 VIETNAM CAPTIVE MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2021-2030 (USD MILLION)
TABLE 7 VIETNAM MERCHANT MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2021-2030 (USD MILLION)
TABLE 8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2021-2030 (USD MILLION)
TABLE 9 VIETNAM CHEMICAL SYNTHETIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2021-2030 (USD MILLION)
TABLE 10 VIETNAM BIOTECH IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2021-2030 (USD MILLION)
TABLE 11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2021-2030 (USD MILLION)
TABLE 12 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2021-2030 (USD MILLION)
TABLE 13 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2021-2030 (USD MILLION)
TABLE 14 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2021-2030 (USD MILLION)
TABLE 15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 16 VIETNAM PHARMACEUTICAL INDUSTRIES IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SIZE, 2021-2030 (USD MILLION)
TABLE 17 VIETNAM BIOTRCHNOLOGY INDUSTRIES IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SIZE, 2021-2030 (USD MILLION)
TABLE 18 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION
FIGURE 2 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DATA TRIANGULATION
FIGURE 3 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DROC ANALYSIS
FIGURE 4 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MULTIVARIATE MODELLING
FIGURE 7 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MARKET TYPE OF END USER COVERAGE GRID
FIGURE 11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF VARIOUS CHRONIC DISORDERS AND THE RISING AGEING POPULATION IS DRIVING THE VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 ANTIBIOTIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN 2023 TO 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
FIGURE 15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, 2022
FIGURE 16 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)
FIGURE 17 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)
FIGURE 18 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE
FIGURE 19 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2022
FIGURE 20 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 21 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 22 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, 2022
FIGURE 24 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, 2023-2030 (USD MILLION)
FIGURE 25 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, CAGR (2023-2030)
FIGURE 26 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, LIFELINE CURVE
FIGURE 27 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2022
FIGURE 28 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2023-2030 (USD MILLION)
FIGURE 29 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, CAGR (2023-2030)
FIGURE 30 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, LIFELINE CURVE
FIGURE 31 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2022
FIGURE 32 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2023-2030 (USD MILLION)
FIGURE 33 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, CAGR (2023-2030)
FIGURE 34 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, LIFELINE CURVE
FIGURE 35 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , 2022
FIGURE 36 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , 2023-2030 (USD MILLION)
FIGURE 37 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , CAGR (2023-2030)
FIGURE 38 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , LIFELINE CURVE
FIGURE 39 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2022
FIGURE 40 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2023-2030 (USD MILLION)
FIGURE 41 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, CAGR (2023-2030)
FIGURE 42 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, LIFELINE CURVE
FIGURE 43 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, 2022
FIGURE 44 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 45 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 46 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 47 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER, 2022
FIGURE 48 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER 2023-2030 (USD MILLION)
FIGURE 49 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 50 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 52 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 53 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 54 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 55 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY SHARE 2022 (%)
